BTC$62,769.00-0.20%
ETH$1,795.23+0.98%
USDT$0.9988-0.02%
BNB$570.12+0.34%
USDC$0.9999+0.01%
XRP$1.07-0.75%
SOL$75.21-1.19%
TRX$0.3248-0.76%
FIGR_HELOC$1.03+1.91%
HYPE$63.84-1.72%
DOGE$0.0721-0.02%
USDS$0.9999+0.02%
RAIN$0.0142-1.58%
LEO$9.55+0.30%
ZEC$507.33-1.11%
WBT$55.10+0.04%
BTC$62,769.00-0.20%
ETH$1,795.23+0.98%
USDT$0.9988-0.02%
BNB$570.12+0.34%
USDC$0.9999+0.01%
XRP$1.07-0.75%
SOL$75.21-1.19%
TRX$0.3248-0.76%
FIGR_HELOC$1.03+1.91%
HYPE$63.84-1.72%
DOGE$0.0721-0.02%
USDS$0.9999+0.02%
RAIN$0.0142-1.58%
LEO$9.55+0.30%
ZEC$507.33-1.11%
WBT$55.10+0.04%
Vanda stock jumped more than 40% in premarket trading after the FDA approved its new drug BYSANTI for Bipolar I disorder and schizophrenia.
Moderna stock dropped over 9% in premarket trading after the FDA refused to review its mRNA-based flu vaccine, citing inadequate study design.
Novo Nordisk stock jumped 8% after Hims & Hers withdrew its knockoff Wegovy pill amid FDA scrutiny and legal threats.
Novo Nordisk shares rose more than 7% in premarket trading after the FDA approved its oral Wegovy weight-loss pill.
Moderna shares fell over 4% after the FDA signaled stricter vaccine approval rules, raising concerns about potential delays for new vaccines.
Biohaven dropped 44% in premarket trading after the FDA declined to approve Vyglxia, citing issues with trial design even as data showed slower disease progression.
Outlook Therapeutics stock crashed 70% in premarket after the FDA rejected its wet AMD drug application, citing insufficient efficacy evidence despite previous trial successes.
Shares of drugmaker Ars Pharmaceuticals crashed over 57% after FDA disapproved its EpiPen alternative.
How will the rally end?